We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

WATERS CORPORATION

Waters Corp. designs, manufactures, sells and services ultra performance liquid chromatography (UPLC), high performan... read more Featured Products: More products

Download Mobile App




Blood Metabolites Tests Helps Tailor Cancer Treatment

By LabMedica International staff writers
Posted on 15 Jun 2016
As a minimally invasive assessment, plasma metabolomic analysis has the potential to complement direct tumoral measurements and, particularly where cancer biopsies are unavailable, and can report on the integrated output of multiple systems including sites of disease.

Testing for metabolic changes in the blood could indicate whether a cancer drug is working as designed, and by measuring how cancer treatment affects the levels of metabolites, the building blocks of fats and proteins, those levels can be used to assess whether the drug is hitting its intended target.

Scientists at the Institute of Cancer Research (London, UK) and a team of international collaborators measured the levels of 180 blood markers in 41 patients with advanced cancers in a phase I clinical trial. More...
The drug pictilisib is designed to specifically target a molecular pathway in cancer cells, called phosphatidylinositide 3-kinase (PI3K), which has key a role in cell metabolism and is defective in a range of cancer types. As cancers with PI3K defects grow, they can cause a decrease in the levels of metabolites in the bloodstream.

Non-targeted liquid chromatography–mass spectrometry (LC-MS) metabolomics was initially used in the preclinical screen as significant changes in plasma metabolites were identified. To follow-up and confirm these preliminary findings, the scientists carried out targeted, quantitative metabolomic analysis by electrospray ionization tandem MS using the AbsoluteIDQ p180 Kit (Biocrates Life Sciences AG, Innsbruck, Austria). Samples were anonymized and analyses were carried out on an Acquity H-class UPLC coupled to Xevo TQ-S triple-quadrupole MS/MS System (Waters Corporation, Milford, MA, USA).

The authors found in a mouse model that the blood levels of 26 different metabolites, which were low prior to therapy, had risen considerably following treatment with pictilisib. Their findings indicated that the drug was hitting its target, and reversing the effects of the cancer on mouse metabolites. Similarly, in humans they found that almost all of the metabolites, 22 out of the initial 26, once again rose in response to pictilisib treatment, as seen in the mice. Blood levels of the metabolites began to increase after a single dose of pictilisib, and were seen to drop again when treatment was stopped, suggesting that the effect was directly related to the drug treatment.

Florence J. Raynaud, PhD, a senior author of the study, said, “We have shown that assessing a patient's metabolites can be a quick and simple way of assessing whether a cancer drug is specifically hitting its intended target in the body. Our study is an important step in the development of new precision cancer therapies, and is the first to show that blood metabolites have real potential to monitor the effects of novel agents. Our method was developed specifically for pictilisib but could now be adapted to discover metabolite markers for other cancer treatments.” The study was published on April 5, 2016, in the journal Molecular Cancer Therapeutics.

Related Links:
Institute of Cancer Research
Biocrates Life Sciences
Waters

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.